Thiazide diuretics in the treatment of hypertension: An update

Journal of the American Society of Nephrology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Salvetti, Antonio ^a   Ghiadoni, Lorenzo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; GLUCOSE; HYDROCHLOROTHIAZIDE; LIPID; LISINOPRIL; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; MAINTENANCE THERAPY; MEDICAL SOCIETY; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 33645462691     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121329     Document Type: Conference Paper

References (30)

1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 335: 827-838, 1990
2. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535, 2003
3. Multiple Risk Factor Intervention Trial Research Group: Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 82: 1616-1628, 1990
4. Davis BR, Furberg CD, Wright JT Jr, Cutler JA, Whelton P: ALLHAT Collaborative Research Group: ALLHAT: Setting the record straight. Ann Intern Med 141: 39-46, 2004
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002
6. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-592, 2003
7. Psaty BM, Lumley T, Furberg CD: Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 292: 43-44, 2004
8. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277: 739-745, 2004
9. Carter BL, Ernst ME, Cohen JD: Hydrochlorothiazide versus chlorthalidone: Evidence supporting their interchange-ability. Hypertension 43: 4-9, 2004
10. Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, Morledge J: Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther 24: 192-198, 1978
11. Salvetti A, Pedrinelli R, Bartolomei G, Cagianelli MA, Cinotti G, Innocenti P, Loni C, Saba G, Saba P, Papi L: Plasma renin activity does not predict the antihypertensive efficacy of chlorthalidone. Eur J Clin Pharmacol 33: 221-226, 1987
12. Materson BJ, Cushman WC, Goldstein G, Reda DJ, Freis ED, Ramirez EA, Talmers FN, White TJ, Nunn S, Chapman RH: Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 15: 348-360, 1990
13. Tuck ML: Metabolic considerations in hypertension. Am J Hypertens 3: 355S-365S, 1990
14. Grobbee DE, Hoes AW: Non-potassium-sparing diuretics and risk of sudden cardiac death. J Hypertens 13: 1539-1545, 1995
15. Cohen HW, Madhavan S, Alderman MH: High and low serum potassium associated with cardiovascular events in diuretic-treated patients. J Hypertens 19: 1315-1323, 2001
16. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18: 1149-1154, 2000
17. Pepine CJ, Cooper-Dehoff RM: Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 44: 509-512, 2004
18. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43: 963-969, 2004
19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290: 2805-2816, 2003
20. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363: 2022-2031, 2004
21. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O: Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21: 1563-1574, 2003
22. Alderman MH, Cohen H, Madhavan S: Diabetes and cardiovascular events in hypertensive patients. Hypertension 33: 1130-1134, 1999
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
24. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1153, 2003
25. The ALLHAT: Officers and coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283: 1967-1975, 2000
26. Salvetti A, Ghiadoni L: Guidelines for antihypertensive treatment: An update after the ALLHAT study. J Am Soc Nephrol 15[Suppl]: S51-S54, 2004
27. Weber MA: New results and analyses expand and modify key interpretations of the ALLHAT Trial. Rev Cardiovasc Med 5: 164-169, 2004
28. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens 21: 1055-1076, 2003
29. Lawes CM, Bennett DA, Feigin VL, Rodgers A: Blood pressure and stroke: An overview of published reviews. Stroke 35: 776-785, 2004
30. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363: 2049-2051, 2004